These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31760568)

  • 21. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
    Wei H; Mao Y; Zhang H; Wu F; Zhang Y
    Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
    Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
    Sun DW; An L; Huang HY; Sun XD; Lv GY
    Clin Transl Oncol; 2021 Jan; 23(1):82-91. PubMed ID: 32462395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
    Long J; Qu T; Pan XF; Tang X; Wan HH; Qiu P; Xu YH
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1188-S1192. PubMed ID: 30539869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 30. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
    Mou H; Yang QA; Yu L; Wang T; Liu K; Shen R; Pan X; Dai Y; Wan Q; Zhou F; Qian L; Chen D; Yau T; Dong X; Wang X; Wang S
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2601-2609. PubMed ID: 33656759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
    Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
    World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
    Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
    Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
    Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
    J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
    Kan G; Dong W
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3063-71. PubMed ID: 26367730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
    Sideras K; de Man RA; Harrington SM; Polak WG; Zhou G; Schutz HM; Pedroza-Gonzalez A; Biermann K; Mancham S; Hansen BE; Bart Takkenberg R; van Vuuren AJ; Pan Q; Ijzermans JNM; Sleijfer S; Sprengers D; Dong H; Kwekkeboom J; Bruno MJ
    Sci Rep; 2019 Jul; 9(1):10677. PubMed ID: 31337865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
    Du J; Zhang E; Huang Z
    Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
    Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
    Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
    Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
    Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.